Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

Yamaguchi K, Shoji H, Yasui H, Oki E, Sakai D, Hamaguchi T, Tsuji A, Oshima T, Tsuda M, Minashi K, Yang J, Guerrero A, Ueno Y, Matsangou M, Gourgioti G, Nakanishi Y, Furuki S, Kuwamoto K, Yamada S, Shitara K

Open source

DOI: 10.1007/s10120-026-01738-7
Published: 2026 Jul
Container: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10120-026-01738-7,
  title = {Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.},
  author = {Yamaguchi K and Shoji H and Yasui H and Oki E and Sakai D and Hamaguchi T and Tsuji A and Oshima T and Tsuda M and Minashi K and Yang J and Guerrero A and Ueno Y and Matsangou M and Gourgioti G and Nakanishi Y and Furuki S and Kuwamoto K and Yamada S and Shitara K},
  year = {2026},
  journal = {Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association},
  doi = {10.1007/s10120-026-01738-7},
  url = {https://doi.org/10.1007/s10120-026-01738-7}
}

RIS

TY  - JOUR
TI  - Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.
AU  - Yamaguchi K
AU  - Shoji H
AU  - Yasui H
AU  - Oki E
AU  - Sakai D
AU  - Hamaguchi T
AU  - Tsuji A
AU  - Oshima T
AU  - Tsuda M
AU  - Minashi K
AU  - Yang J
AU  - Guerrero A
AU  - Ueno Y
AU  - Matsangou M
AU  - Gourgioti G
AU  - Nakanishi Y
AU  - Furuki S
AU  - Kuwamoto K
AU  - Yamada S
AU  - Shitara K
PY  - 2026
JO  - Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
DO  - 10.1007/s10120-026-01738-7
UR  - https://doi.org/10.1007/s10120-026-01738-7
ER  -

APA

K, Y., H, S., H, Y., E, O., D, S., T, H., A, T., T, O., M, T., K, M., J, Y., A, G., Y, U., M, M., G, G., Y, N., S, F., K, K., S, Y., & K, S. (2026). Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. https://doi.org/10.1007/s10120-026-01738-7

Source records

pubmed · retrieved 2026-09-26T07:52:23.488Z
europe-pmc · retrieved 2026-09-26T07:52:23.498Z